Regencell Bioscience Holdings Limited

RGC

KYG7487R1002

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 09/05/2024 BST			5-day change	1st Jan Change
5.56 ^USD	-10.61%		+4.32%	-47.05%

2023	Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2023	CI
2023	Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2022	CI

Regencell Bioscience Holdings Limited has filed an IPO in the amount of $17.724375 million.

March 22, 2021 at 04:00 am

Regencell Bioscience Holdings Limited has filed an IPO in the amount of $17.724375 million. Security Name: Ordinary Shares Security Type: Common Stock

Latest news about Regencell Bioscience Holdings Limited

Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2023	27/10/23	CI
Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2022	15/06/23	CI
Regencell Bioscience Holdings Limited Promotes Yat-Pui Au from Senior Vice President to Chief Business Officer	28/02/23	CI
Regencell Bioscience Holdings Limited Announces the Resignation of Yi-Chung Chao as Chief Medical Officer, with Effect from December 28, 2022	22/12/22	CI
Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2022	31/10/22	CI
Regencell Bioscience Holdings Limited Announces its Standardized Formulae Shows Reduce ADHD and ASD Symptoms in Interim Results of its Second Efficacy Trial	12/09/22	CI
Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2021	02/06/22	CI
Regencell Bioscience Holdings Limited Announces Additional Earth Efficacy Trial Results Corroborating Effectiveness of Its Investigational Liquid-Formula Rgc-Cov19tm in Eliminating Mild to Moderate Covid-19 Symptoms Within the 6-Day Treatment Period	18/05/22	CI
Regencell Bioscience Holdings Limited Announces Resignation of Tien Hsiang Chau as Chief Financial Officer	26/04/22	CI
Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19 Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial	17/02/22	CI
Certain Warrants of Regencell Bioscience Holdings Limited are subject to a Lock-Up Agreement Ending on 12-JAN-2022.	11/01/22	CI
Certain Ordinary Shares of Regencell Bioscience Holdings Limited are subject to a Lock-Up Agreement Ending on 12-JAN-2022.	11/01/22	CI
Regencell Bioscience Holdings Limited Appoints William Wing-Yan Lo to Its Board of Directors	13/12/21	CI
Regencell Bioscience Holdings Limited Announces Cheung Ming Wong as Independent Director	17/11/21	CI
Regencell Bioscience : Forms Joint Venture to Offer COVID-19 Treatment to Select Asia Pacific Countries	02/09/21	MT
Regencell Bioscience Holdings Limited Appoints James Wai Hong Chung as Chief Operating Officer	01/09/21	CI
Top Premarket Decliners	26/08/21	MT
DJ Industrial : Top Premarket Gainers	25/08/21	MT
DJ Industrial : Wall Street Set for Gains, Jackson Hole Symposium Eyed	23/08/21	MT
DJ Industrial : Top Premarket Decliners	23/08/21	MT
Update: Regencell Bioscience Raises $24.9 Million from IPO -- Shares More Than Triple Amid Heavy Trading Volume	20/08/21	MT
Regencell Bioscience : Says IPO Raised $24.9 Million	20/08/21	MT
Regencell Bioscience : Hong Kong's Regencell Bioscience Rises in Nasdaq Debut	16/07/21	MT
Regencell Bioscience Holdings Limited has completed an IPO in the amount of $21.85 million.	15/07/21	CI
Regencell Bioscience Holdings Limited has filed an IPO in the amount of $17.724375 million.	22/03/21	CI

Chart Regencell Bioscience Holdings Limited

Duration

Period

Chart Regencell Bioscience Holdings Limited

More charts

Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
REGENCELL BIOSCIENCE HOLDINGS LIMITED	-47.05%	72.35M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B